Medivation Inc. (MDVN) has reported a net loss of 42 cents per share in the third quarter of 2009, exceeding the Zacks Consensus Estimate of a net loss of 39 cents. However, net loss declined from the year-ago loss of 68 cents.  Revenue for the quarter was $16.3 million, consisting of partial recognition of the non-refundable upfront payment of $225 million received from Pfizer (PFE) in October 2008. The upfront payment is being recognized on a straight-line basis through the first quarter of 2012. Revenues were nil in the year-ago period.  Operating expenses grew from $20.6 million in the year-ago period to $27.6 million in the quarter. Research and development expenses increased to $21.5 million as a result of greater clinical trials expenses which were partially offset by a cost share reimbursement under the company’s agreement with Pfizer. With Dimebon and MDV3100 moving into advanced ...

Dendreon’s Reached Orbit… Now Who’s Next?

by Robert Williams, Publisher

When the opening bell rang on Tuesday morning, as the broader market sagged, shares of Dendreon Corp. (Nasdaq: DNDN) sprinted out of the gates, rising by 5.7%.

Unless you live in a cave, you should know about this biotech stock.

Back in April, shares went “parabolic,” blasting 454% higher during the month.

(That’s not a typo. The stock increased almost five-fold over the course of a single month, rendering the S&P 500’s 10% gain over the same period completely insignificant.)

With an impressive move like that, you might think the run is over. But shares will likely head higher still…

You see, Dendreon is blazing a brand new path in biotech. Its prostate cancer drug, Provenge, which it just submitted to the FDA for approval, is the first

...

Put These Two Promising Biotech Stocks on Your Watch List

by Louis Basenese, Small Cap and Special Situations Expert Friday, November 6, 2009: Issue #1132

All the hoopla surrounding the biotech stock, Dendreon Corp. (Nasdaq: DNDN), this year is well deserved.

After all, the market potential for its prostate cancer treatment, Provenge, is significant. This year, 190,000 new cases of prostate cancer are expected, with 27,000 deaths from the disease. That makes it the most common non-skin cancer in the United States and the third most common cancer worldwide.

But Provenge takes a novel approach to treatment. The drug is the first active immunotherapy to improve survival by training a patient’s immune system to attack the cancer. And since it uses the body’s natural defenses, patients only report flu-like symptoms instead of the nasty side effects associated with chemotherapy.

This

...

MannKind Pharma’s (MNKD) third quarter loss per share came in at 42 cents, better than the Zacks Consensus Estimate of 49 cents and loss of 67 cents reported in the year-ago period. The company does not have any revenue stream at present -- its lead product, Afresa (inhaled insulin for the treatment of type I and type II diabetes) is currently under US Food and Drug Administration (FDA) review. MannKind filed a New Drug Application (NDA) for Afresa with the FDA in March 2009, which was subsequently accepted in May 2009. The company has been assigned a Prescription Drug User Fee Act (PDUFA) date of January 16, 2010. Operating expenses for the third quarter declined 38% to $42.8 million, primarily due to a huge reduction in R&D expenses. Reduced costs associated with the clinical development of Afresa along with a decline in manufacturing costs brought down ...

  Amgen (AMGN) reported third quarter earnings per share of $1.47, well above the Zacks Consensus Estimate of $1.26 and 21% above the year-ago earnings of $1.21. Cost cuts and a lower tax rate helped boost the top-line despite a 2% decline in total revenues, which came in at $3,812 million. Total product sales decreased 1% to $3,736 million. While sales in the U.S. were relatively unchanged at $2,918 million, international sales declined 4% to $818 million mainly due to the unfavorable impact of foreign exchange (Fx) fluctuation, which affected sales by approximately $76 million. Aranesp sales declined 19% to $685 million (U.S. - $333 million, down 27%; ex-U.S. - $352 million, down 9%), mainly due to a decline in demand reflecting the negative impact, primarily in the supportive cancer care setting, of additional product label changes which occurred in August 2008. Aranesp continued to lose share ...

Recently, Dendreon Corp. (DNDN) announced that it intends to file an amendment to its existing Biologic License Application (BLA) for its prostate cancer vaccine Provenge in Nov. 2009. We believe that the US Food and Drug Administration (FDA) will approve Provenge in the first half of 2010 based on the positive phase III IMPACT (IMmunotherapy for Prostrate AdenoCarcinoma Treatment) trial results announced in Apr. 2009.   If approved, Dendreon will become the first company to receive approval for an anti-cancer immunotherapy based vaccine. In development studies, Provenge boosted survival rates in men with advanced prostate cancer beyond any currently available treatments. Unlike traditional vaccines that prevent diseases, Provenge treats it by stimulating the body's own immune system to attack cancer cells. We also expect the company to announce a partner for Provenge in Europe soon while Dendreon itself will market the drug in the U.S.   Prostate cancer ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 30, 2009

DrStockPick.com Stock Report!

COV, PWRM, MSFT, CSRH, NKE, CVAT, ABT

**************************************************************

COV, Covidien plc

COV engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings worldwide. The company operates through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products, and Medical Supplies.

COV said Wednesday it received Food and Drug Administration clearance for its new endotracheal tube, a device that helps patients breathe.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the

...

Dendreon Corporation (DNDN) is likely to become the first company to receive approval from the US Food and Drug  Administration (FDA) for an anti-cancer, immunotherapy based vaccine, as it released phase III IMPACT (IMmunotherapy for Prostrate AdenoCarcinoma Treatment) trial results for its key product candidate, Provenge, in April 2009. Provenge boosted survival rates in men with advanced prostate cancer beyond any currently available treatments. Dendreon intends to file an amendment to its existing Biologic License Application (BLA) in the fourth quarter of 2009. We believe that the FDA will approve Provenge in the first half of 2010 based on the positive late-stage study results. We also expect the company to announce a partner for Provenge in Europe soon while Dendreon itself will market the drug in the U.S. We believe Provenge could have blockbuster potential if it is approved by the regulators. Prostate cancer is the most ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday September 28, 2009

DrStockPick.com Stock Report!

XRX, PWRM, ABT, CSRH, CMCSA, CVAT, FMCN

**************************************************************

XRX, Xerox Corp.

XRX engages in the development, manufacture, marketing, servicing, and financing of document equipment, software, solutions, and services worldwide.

XRX said Monday it will buy Affiliated Computer Services Inc. for $6.4 billion in cash and stock to create a $22 billion business that combines XRX’s copiers, printers and document management services with the “business process outsourcing” of Dallas-based ACS., joining the expensive race among technology companies to broaden their offerings.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in

...

Recently, Incyte Corporation (INCY) presented impressive data from a mid-stage trial for its pipeline candidate INCB18424 for psoriasis treatment. The phase IIb trial, carried out on 200 patients over a period of three months, compared three once-daily doses of the drug compared to the placebo. It was observed that patients treated with INCB18424 had a statistically significant improvement over the placebo in reducing total lesion score (erythema + scaling + thickness), which was also the primary endpoint of the trial. In addition, the trial met its secondary endpoint which was the Physician Global Assessment score and the Psoriasis Area and Severity Index score. Apart from psoriasis, Incyte is conducting trials of INCB18424 for several other indications which include myelofibrosis, polycythemia vera/essential thrombocythemia, rheumatoid arthritis, refractory prostate cancer and multiple myeloma. Incyte has other potential candidates targeting treatment for diabetes, breast cancer and HIV. However, the ...